Biohaven Ltd.
BHVN · the NYSE · USD · Market cap $2.0B · 274 employees
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide.
FAIL · Does not pass the screenPrice as of 20 Nov 2026Daily close, not a live quote
Screened 2026-11-20 · the tape above runs as of 14:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price12.39 USD at the 20 Nov 2026 close
- Our value readUndervalued vs our fair value, as of 20 Nov 2026
- Our regime readMarkup, as of 15 Nov 2026
- Ethical screenDoes not pass
- OptionsOpen interest leans to puts (put/call 2.87)
- Last reviewed20 Nov 2026 (1 day ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $9.00 to $25.80, base estimate $23.00 (screen dated 2026-11-20).
- Trend Markup
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 2.87, read 2026-11-19
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markup label.
Biohaven Ltd. holds its Markup at $12.39. Consolidating, no directional conviction, held for 16 days.
| Phase | Markup |
| Quantitative state | Consolidating, no directional conviction, held for 16 days |
| Price at the screen | $12.39 |
| Valuation | N/A trailing · -8.64 forward price to earnings |
| Values screen | FAIL · score 70.0 |
| Beta | 3.14 |
Five Screens: BHVN's Results
FAIL. Debt ratio
| Test | Figure | Limit | Status |
|---|---|---|---|
| Business activity | Permissible | Permissible core business | Pass |
| Debt load | 63.04% | Below 33% | Fail |
| Interest-bearing cash | 19.75% | Below 33% | Pass |
| Receivables | 50.94% | Below 49% | Fail |
Definitions, sources and threshold rules: ticker values-screen methodology.
The Ethical ReadWhy It Falls Short, in Plain English
Biohaven's business is in a permissible area, but its interest-bearing debt is about 63% of the company, well over the ~33% line, so it does not pass on the financial screens. Its receivables are also high.
Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.
Follow this verdict
Get an email when BHVN's ethical verdict changes
Today BHVN does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Undervalued to fair value, as of 20 Nov 2026: it trades at roughly a 46% discount to our $23.00 fair value.
USD, 2026-11-20 screen. A 46.1% under base.
Street: 15 covering, consensus Buy. Average target +86%.
Biotech Pipeline Lacks Numbers and Ethical Clarity
Imagine betting on a lab that burns cash on every trial with no profits in sight. Biohaven develops treatments for immunology and oncology yet posts zero margins and returns on equity of minus three hundred thirty three per cent. The forward multiple sits at minus seven point nine times while the share price of fifteen dollars forty four sits below our calculated fair value.
Analysts like the story and set a median target near twenty dollars. We pass outright. The ethical screen returns insufficient data because basic financial ratios are missing, so no verdict on governance or long term impact is possible.
Without those details the apparent margin of safety stays unusable. Funding cycles in early stage biotech add further opacity that no consensus rating can fix. Analysis, not advice.
| Forward P/E | -8.6x |
| EPS, trailing | -3.76 |
| EPS, forward | -1.53 |
| Profit margin | 0.0%currently unprofitable |
| FCF yield | -11.47% |
| Current ratio | 3.05comfortably covers its short-term bills |
| Beta | 3.14much more volatile than the market |
| Short interest, float | 0.13% |
| 52-week range | 8.03 - 18.24 |
| Market cap | $2.0B |
| Employees | 274 |
BHVN-specific watchpoints · The things to watch: it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Metric definitions and interpretation rules: ticker-page methodology.
Every Entry, As Written
Since the last review it saw its composite score rise.
The framework has shifted from distribution to markup since the last review.
The framework has shifted from markdown to distribution since the last review. Since the last review it saw its composite score rise.
The framework has shifted from markup to markdown since the last review.
Ethical screening: FAIL.
Written on its date, before the outcome; never pruned.
- Could Graves Data Alter The Investment Case For Biohaven (BHVN)? Yahoo Finance · 8d ago
- Biohaven Drives New Research in Graves' Disease: Phase 3 Pivotal Trial with BHV-1300 Underway and Three Scientific Posters at the 2026 American Thyroid Association Annual (ATA) Meeting Yahoo Finance · 16d ago
- Is Biohaven (BHVN) Undervalued After Its Narrower Loss And BHV 1420 Data? Yahoo Finance · 22d ago
- Biohaven Reports Recent Business Developments and Third Quarter 2026 Financial Results Yahoo Finance · 23d ago
- Wall Street Analysts Believe Biohaven Ltd. (BHVN) Could Rally 43.49%: Here's is How to Trade Yahoo Finance · 23d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $9.08 | +20.2% | · | $1,202 | +20.2% |
| 2 months | $9.17 | +19.0% | · | $1,190 | +19.0% |
| 3 months | $9.91 | +10.1% | · | $1,101 | +10.1% |
| 6 months | $11.44 | -4.6% | · | $954 | -4.6% |
| 1 year | $16.79 | -35.0% | · | $650 | -35.0% |
| 2 years | $35.06 | -68.9% | · | $311 | -68.9% |
| 3 years | $23.85 | -54.3% | · | $457 | -54.3% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever BHVN does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.